Clinical trial transparency in the pharmaceutical industry is continually evolving, and to stay on top of the news, TrialAssure brings a bi-weekly round-up of some of the key stories. Select recent and relevant stories are as follows:
EMA weighs COVID-19 data transparency, not ready to resume full clinical data publication – RAPS.org
“In a response to officials at Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) and the Cochrane Collaboration, European Medicines Agency (EMA) Executive Director Guido Rasi said the agency is trying to figure out how to be transparent with regard to clinical trial data for products it reviews to treat or prevent coronavirus disease (COVID-19).”
Read more on RAPS.org
International community joins WHO in supporting open COVID-19 research, science – Homeland Preparedness News
More than 30 countries and international partners/institutions have rallied behind the COVID-19 Technology Access Pool (C-TAP), a new initiative from the World Health Organization (WHO) and Costa Rica designed to make scientific tools to fight COVID-19 universally available. Specifically, it calls for public disclosure of gene sequences and data and transparency in the publication of clinical trial results, among other things.
Read more on open COVID-19 research
New transparency webinar offered for free – MMS Holdings and TrialAssure
This Expert Insights webinar will focus on key elements of current transparency regulations, including the background and history of the European Medicines Agency (EMA) Policy 0070 and Health Canada Public Release of Clinical Information (PRCI) requirements for the publication of clinical trial data. Key requirements of both health authorities will be discussed in-depth, including similarities and differences. Additionally, attendees will learn about the future of document sharing and what will be required to disclose publicly in the years to come.
Share Other Health Data In Real-Time Like It’s A Pandemic – ReadWrite
Near real-time data-sharing on the COVID-19 cases as they come in has been at the forefront of the fight against the pandemic. Particular countries without the privacy restrictions of the U.S. or Europe are sharing detailed patient information, not only with physicians, but the public to help each individual work with the best information. The countries who have thus far proven to be the most effective in fighting COVID-19 are also the ones that have invested heavily in data-sharing capabilities.
Learn about data sharing in Singapore
